on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Secures Royalty Monetization Deal Worth Up to EUR 128.88 Million
BRAIN Biotech AG has entered into a royalty monetization agreement for its investigational pharma compound deucrictibant with Royalty Pharma. The deal is valued at up to EUR 128.88 million.
The agreement includes an upfront payment of EUR 18.41 million. Additional potential regulatory milestones could bring in up to EUR 18.42 million. Long-term sales milestones may add another EUR 92.05 million.
Deucrictibant, part of BRAIN Biotech's BioIncubator pipeline, is in clinical development by Pharvaris NV for Hereditary Angioedema. Net proceeds will fund future growth and loan repayments. The transaction is subject to customary closing conditions.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news